Publications by authors named "K Miyagi"
Rationale: Although the mortality of severe coronavirus disease 2019 (COVID-19) has decreased after the emergence of the Omicron variant, it remains high in patients on hemodialysis (HD). Remdesivir (RDV) is considered as the first line drug for hospitalized COVID-19 patients, however the evidence regarding the usage in HD patients is lacking because clinical trials of RDV have excluded HD patients for safety reasons. Thus, accumulation of knowledge on the regimen, efficacy, and tolerability of RDV in HD patients is important.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined the clinical characteristics and risk factors associated with severe COVID-19 cases caused by the XBB variant in Okinawa, Japan, during mid-2023.
- - Out of 367 hospitalized patients, 18.5% were classified as severe, with older age and underlying health conditions linked to a higher mortality rate (13.2% in severe cases vs. 3.0% in mild cases).
- - Notably, diabetes mellitus increased the risk for severe COVID-19, while receiving the bivalent omicron booster significantly reduced the severity of the disease.
Background/objectives: Lipid metabolism and adiponectin modulate erythropoiesis in vitro and in general population studies and may also affect responsiveness to erythropoietin in patients undergoing haemodialysis (HD). However, little is known about the impact of lipid-associated biomarkers on reticulocyte production and erythropoietin resistance index (ERI) in patients undergoing HD. Therefore, we aimed to investigate their impacts in 167 stable patients undergoing HD.
View Article and Find Full Text PDFBackground: There have been few descriptions in the literature on long-term enzyme replacement therapy (ERT) in patients with advanced late-onset Pompe disease (LOPD).
Objectives: This study aimed to assess the efficacy and limitations of ERT in advanced LOPD patients.
Methods: We retrospectively reviewed the clinical courses of patients with advanced LOPD (two juvenile-onset and five adult-onset patients) who were treated with recombinant human alglucosidase alfa to examine improvements achieved with and limitations of ERT until their death or when switching to avalglucosidase alfa occurred.